Workflow
Harvard Bioscience(HBIO) - 2024 Q4 - Annual Results
HBIOHarvard Bioscience(HBIO)2025-03-12 11:00

Revenue Performance - Fourth quarter 2024 revenues were 24.6million,down12.424.6 million, down 12.4% from 28.2 million in Q4 2023[3] - For the full year 2024, revenues totaled 94.1million,down16.294.1 million, down 16.2% from 112.3 million in 2023[5] - The company expects Q1 2025 revenues to be between 19millionand19 million and 21 million, with a gross margin of 56% to 58%[8] Profitability - Net income for Q4 2024 was 18thousand,comparedtoanetlossof18 thousand, compared to a net loss of (1.8) million in Q4 2023[4] - The net loss for 2024 was (12.4)million,comparedtoanetlossof(12.4) million, compared to a net loss of (3.4) million in 2023[6] - Adjusted operating income for the year ended December 31, 2024, was 5,294,downfrom5,294, down from 13,075 in 2023, reflecting a decrease of 59.5%[26] - Adjusted net income for the three months ended December 31, 2024, was 2,686,comparedto2,686, compared to 1,731 in the same period of 2023[26] Margins - Gross margin for Q4 2024 was 57.1%, a slight decrease from 58.0% in Q4 2023[3] - Adjusted EBITDA for Q4 2024 was 3.0million,downfrom3.0 million, down from 3.6 million in Q4 2023[4] - Adjusted EBITDA for the three months ended December 31, 2024, was 2,991,representingamarginof12.22,991, representing a margin of 12.2%[26] - The company reported an operating margin of 0.0% for the three months ended December 31, 2024, down from 1.0% in 2023[26] Cash Flow - Cash provided by operations in Q4 2024 was 1.7 million, compared to 4.3millioninQ42023[4]NetcashprovidedbyoperatingactivitiesforthethreemonthsendedDecember31,2024,was4.3 million in Q4 2023[4] - Net cash provided by operating activities for the three months ended December 31, 2024, was 1,725, compared to 4,303inthesameperiodof2023[24]Cashandcashequivalentsattheendoftheperiodwere4,303 in the same period of 2023[24] - Cash and cash equivalents at the end of the period were 4,108, a decrease from 4,283attheendofthepreviousyear[24]DebtandFinancingTotaldebt,includingunamortizeddeferredfinancingcosts,was4,283 at the end of the previous year[24] Debt and Financing - Total debt, including unamortized deferred financing costs, was 33,242 as of December 31, 2024, compared to 32,840in2023[27]Thecompanyincurred32,840 in 2023[27] - The company incurred 1,000 in repayment of term debt during the three months ended December 31, 2024[24] Cost Management and Product Development - The company is focusing on cost management to improve operating and financial performance amid market uncertainties[3] - New products, including SoHo™ telemetry systems and MeshMEA™ organoid systems, have received strong market interest[3] - Stock-based compensation for the year ended December 31, 2024, was 4,340,downfrom4,340, down from 5,000 in 2023[26]